Revolutionary Optical Technology will be deployed in new Monitors that will detect patient’s blood oxygen levels more accurately
LOS ANGELES, March 26 /PRNewswire/ -- Pulse-oximeters are the medical standard for monitoring a patient’s blood oxygen and pulse rate and have been in use since the late 1980s. These monitors are a vital tool in assessing a patient’s well being during regular exams, surgery and in hospital ICUs world-wide. The technology was invented over 20 years ago and relies on light to detect this vital parameter.
These monitors have one major weakness; they are only calibrated once at the point of manufacture. The expected accuracy of the patient data is based on an initial clinical study, performed under controlled conditions and in a laboratory setting. Once in use, there is no option to verify that a monitor actually displays correct data, relied upon to make critical medical treatment decisions.
Medtor LLC has recently obtained a global exclusive license to a patented technology portfolio that allows these monitors to continually check and calibrate their accuracy while in use on a patient. Deploying this optical self-check technology will greatly enhance patient safety and will significantly reduce the chance of incorrect clinical decisions that can lead to serious medical conditions.
Traditional ‘old technology’ monitors have shown errors of more than double the expected accuracy in several clinical studies performed in the U.S. and the U.K. Medtor LLC’s Wavesmart(TM) optical technology fully addresses this significant weakness in current patient monitors.
The technology is available for implementation now and is fully compatible with the hardware currently provided by all leading patient monitor manufacturers. Implementation is simple and can be accomplished in newly produced monitors, subsequent to required regulatory approvals.
CONTACT: Thomas M Dietiker of Medtor LLC, +1-310-561-8468,
tdietiker@medtorllc.com
